Citation only
via Europe PMC
Immune-metabolic convergence in skeletal remodeling disorders: shared osteoimmune, senescent and lipid mechanisms across aging-related and immune-mediated bone disease.
Frontiers in immunology · 2026
Cellular senescence
Chronic inflammation
Partial reprogramming (OSK)
Cell culture / in vitro
Human
In vitro
Review
Abstract
Bone and joint disorders of the aging musculoskeletal system are conventionally treated as separate clinical entities. This disease-centered view aids diagnosis but obscures the immune, inflammatory, senescent and metabolic programs they share. This Review compares five of them, grouped by etiology rather than by age: two aging-driven remodeling disorders, osteoporosis (OP) and osteoarthritis (OA); two immune-mediated arthritides in which aging modifies rather than causes the skeletal outcome, rheumatoid arthritis (RA) and psoriatic arthritis (PsA); and one focal, largely monogenic disorder included as a boundary case, Paget's disease of bone (PDB). RA and PsA are not treated as age-related diseases; they are included because they show most directly that immune activation alone can redirect skeletal remodeling. The review is narrative and mechanism-oriented, based on a structured, auditable search (Section 2); we compare evidence across diseases rather than claim exhaustive synthesis. Skeletal aging, immunosenescence, inflammaging(definition) and lipid dysregulation converge on five nodes: the receptor activator of nuclear factor-κB ligand (RANKL)-osteoprotegerin (OPG) axis, the interleukin-17/tumor necrosis factor-α/interleukin-6 network, senescence(definition)-associated secretory phenotype (SASP) amplification, phospholipid peroxidation and ferroptosis, and Wnt-sclerostin-Dickkopf-1 (DKK-1) balance. Across diseases these nodes generate different skeletal outputs: systemic bone loss in OP; cartilage degeneration with subchondral remodeling in OA; erosion with impaired repair in RA; erosion combined with ectopic bone formation in PsA; and focal high-turnover remodeling in PDB. Disease identity, we argue, is set by the sign and relative weighting of node activity rather than by which nodes are engaged; the opposing direction of DKK-1 regulation in RA and PsA is the clearest example. Ferroptotic injury is resolved by cell type rather than treated as uniformly harmful, and PDB is retained as a comparator showing that shared-node activation is permissive rather than deterministic. Candidate biomarkers and pathway-directed therapies are summarized with their translational gaps. Every disease × mechanism combination is graded on a four-level evidence scheme (E1, established human evidence, to E4, indirect or <i>in vitro</i> only) defined in Section 2. A cross-disease, mechanism-informed approach may improve risk stratification, identify treatable endotypes, and guide future trials in immune-metabolic skeletal disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fimmu.2026.1949165
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
TT, G., HX, Z., & QD., J. (2026). Immune-metabolic convergence in skeletal remodeling disorders: shared osteoimmune, senescent and lipid mechanisms across aging-related and immune-mediated bone disease. <em>Frontiers in immunology</em>. https://doi.org/10.3389/fimmu.2026.1949165
Vancouver
TT G, HX Z, QD. J. Immune-metabolic convergence in skeletal remodeling disorders: shared osteoimmune, senescent and lipid mechanisms across aging-related and immune-mediated bone disease. Frontiers in immunology. 2026. doi:10.3389/fimmu.2026.1949165.
BibTeX
@article{guo2026Immune,
title = {Immune-metabolic convergence in skeletal remodeling disorders: shared osteoimmune, senescent and lipid mechanisms across aging-related and immune-mediated bone disease.},
author = {Guo TT and Zheng HX and Jiang QD.},
journal = {Frontiers in immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1949165},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Endocrinology and Metabolism 2023
Open access · CC-BY
Skeletal Senescence with Aging and Type 2 Diabetes
Bone research 2026
Open access · OA
Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation.
Cellular & Molecular Biology Letters 2023
Open access · CC-BY
Cellular senescence in skeletal disease: mechanisms and treatment
Frontiers in immunology
Open access · OA
Immune–metabolic convergence in skeletal remodeling disorders: shared osteoimmune, senescent and lipid mechanisms across aging-related and immune-mediated bone disease
Frontiers in Endocrinology 2026
Open access · CC-BY
The role and mechanisms of bone microenvironment regulators in osteoporosis: novel intervention strategies for addressing the challenges of aging
Biocell 2026
Open access · OA